Loading...
Market
How many countries will Neuraceq be approved in by end of 2026?
2
Resolution / Starting Odds
Less than 20 • 25%
20 to 30 • 25%
31 to 40 • 25%
More than 40 • 25%
Regulatory approval announcements or Lantheus press releases
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Adding Neuraceq to Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings Inc. has agreed to acquire Life Molecular Imaging for an upfront payment of $350 million, with potential additional payments of up to $400 million based on future sales milestones. The acquisition aims to bolster Lantheus' position in the growing Alzheimer's disease radiodiagnostic market by adding Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's disease. The transaction is expected to enhance Lantheus' growth profile and establish a commercial Alzheimer's disease franchise. Life Healthcare Group Holdings, the current owner of Life Molecular Imaging, plans to return the net proceeds from the upfront payment to shareholders within 12 months of the deal's completion, expected in the second half of 2025.
View original story
Similar markets
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
10-14 countries • 25%
5-9 countries • 25%
1-4 countries • 25%
15 or more countries • 25%
More than 15 • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 5 new treatments • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 120 • 25%
Less than 50 • 25%
50 to 80 • 25%
81 to 120 • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
No • 50%
Yes • 50%
One • 25%
None • 25%
Two • 25%
Three or more • 25%
11-15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
More than 15 countries • 25%
More than 60 • 25%
20 to 40 • 25%
Less than 20 • 25%
40 to 60 • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%